Vitamin D Receptor Activator Selectivity in the Treatment of Secondary Hyperparathyroidism: Understanding the Differences Among Therapies

Author： Brancaccio Diego  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.67, Iss.14, 2007-01, pp. : 1981-1998

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK: A Chronic Kidney Disease Markov Model

By Nuijten Mark  

Clinical Drug Investigation, Vol. 30, Iss. 8, 2010-08 ,pp. : 545-557

Adis International

Access to resources Recommend Favorite

Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy

By Eandi Mario  

PharmacoEconomics, Vol. 28, Iss. 11, 2010-11 ,pp. : 1041-1054

Adis International

Access to resources Recommend Favorite

Vitamin D Receptor is a Novel Drug Target for Ovarian Cancer Treatment

By  

Current Cancer Drug Targets, Vol. 6, Iss. 3, 2006-05 ,pp. : 229-244

Bentham Science Publishers

Access to resources Recommend Favorite

A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-&ggr; as a New Target Therapy in the Treatment of Human Urological Cancer

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 1, 2009-03 ,pp. : 76-83

Bentham Science Publishers

Access to resources Recommend Favorite

Vitamin D and Vitamin D Analogs in Cancer Treatment

By  

Current Drug Targets, Vol. 3, Iss. 1, 2002-02 ,pp. : 85-94

Bentham Science Publishers

Access to resources Recommend Favorite